Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO

BACKGROUND: FOLFOXIRI/bevacizumab (bev) is a first-line regimen of proven activity and efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises concerns about the efficacy of treatments after progression. METHODS: We performed a pooled analysis of treatments after pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossini, Daniele, Lonardi, Sara, Antoniotti, Carlotta, Santini, Daniele, Tomasello, Gianluca, Ermacora, Paola, Germani, Marco Maria, Bergamo, Francesca, Ricci, Vincenzo, Caponnetto, Salvatore, Moretto, Roberto, Zaniboni, Alberto, Pietrantonio, Filippo, Buonadonna, Angela, Ritorto, Giuliana, Masi, Gianluca, Latiano, Tiziana Pia, Rapisardi, Stefania, Falcone, Alfredo, Cremolini, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782547/
https://www.ncbi.nlm.nih.gov/pubmed/33024268
http://dx.doi.org/10.1038/s41416-020-01089-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782547/
https://www.ncbi.nlm.nih.gov/pubmed/33024268
http://dx.doi.org/10.1038/s41416-020-01089-9

Ejemplares similares